Summary of Use during Lactation

No information is available on the clinical use of blinatumomab during breastfeeding. Because blinatumomab is a large protein molecule with a molecular weight of about 54,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[1] Until more data become available, blinatumomab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during blinatumomab therapy and for at least 48 hours after treatment.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.

Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22:350–66. [PubMed: 36931808]

Substance Name

Blinatumomab

CAS Registry Number

853426-35-4

Drug Class

Breast Feeding

Lactation

Milk, Human

Antibodies, Monoclonal

Antineoplastic Agents